StockData

MDxHealth vs Exagen

MDXH and XGN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MDXH and XGN compare

Exagen grew revenue faster over the last twelve months (20.8% versus 19.8% for MDxHealth).

Exagen keeps more of each dollar of sales as profit, with a net margin of −26.6% compared with −31.1% at MDxHealth.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMDXHXGN
Size and price
Market cap–$91.1M
Share price$0.149$3.76
Change, 1 year−95.9%−58.3%
Change, 5 years−98.4%−65.9%
Beta (5Y)3.132.77
Employees364220
StockData Score
Total score55
Valuation score00
Growth score33
Performance score11
Health score11
Dividend score00
Valuation
P/S–1.3×
P/B–7.5×
FCF yield–−8.3%
Fair value–$3.42
Margin of safety–−9.9%
Growth
Revenue growth (TTM)19.8%20.8% (better)
Revenue growth, 5Y average42.3% (better)9.7%
Profitability
Gross margin64.5% (better)58.6%
Operating margin−13.4% (better)−18.6%
Net margin−31.1%−26.6% (better)
FCF margin−3.1% (better)−10.7%
Return on equity–−114%
Return on invested capital–−86.1%
Financial health
Debt / equity–1.87
Interest coverage−0.6× (better)−2.6×
Current ratio1.083.18 (better)
Altman Z-score–−6.08
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions32.3%34.1%
Held by insiders–29.2%
Insider net buying, 12 months$991K (better)−$769K
Short interest, % of float–4.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.